Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R. Mirza, Ursula A. Matulonis, Jonathan A. Ledermann et al.|New England Journal of Medicine|2016Cited by 2.5k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, Cristiana Sessa, Andreas du Bois et al.|Annals of Oncology|2019Cited by 1.2k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability StudyJacques Bonneterre, Mia von Euler, Beat Thürlimann et al.|Journal of Clinical Oncology|2000Cited by 840
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA groupD. Timmerman, L. Valentin, Lieveke Ameye et al.|BMJ|2010Cited by 473
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Anne Floquet et al.|The Lancet Oncology|2021Cited by 412